Turksever C, et al. – The outcome predictors of aflibercept in neovascular age–related macular degeneration pretreated with ranibizumab were contemplated, on the basis of a treat–and–extend regimen (TER). The findings brought to light the fact that the baseline hyperreflective foci (HRF) presence speculated an improved morphological outcome. However, subretinal fluid (SRF) predicted a shorter recurrence–free treatment interval (RFTI) and intraretinal fluid (IRF) a longer RFTI after shifting from ranibizumab to aflibercept within a TER.